BGLU5 Antibody

What is mGluR5 and why are antibodies against it important in neuroscience research?

mGluR5 (metabotropic glutamate receptor 5) is a G-protein coupled receptor for glutamate that plays a crucial role in synaptic plasticity and neural network modulation. It belongs to Group I metabotropic glutamate receptors along with mGluR1. Ligand binding to mGluR5 triggers signaling via G proteins, activating a phosphatidylinositol-calcium second messenger system and generating calcium-activated chloride currents .

Antibodies against mGluR5 are valuable research tools for:

• Defining expression patterns and localization in native tissues

• Capturing mGluR5 proteins for analytical studies

• Investigating mGluR5-associated neurological disorders such as encephalitis

• Elucidating the pathophysiology of conditions like Ophelia syndrome (associated with Hodgkin lymphoma)

• Studying receptor trafficking, internalization, and signaling mechanisms

What are the validated applications for mGluR5 antibodies?

Based on manufacturer data and published research, mGluR5 antibodies have been validated for multiple applications:

When selecting antibodies for specific applications, verify validation data on the manufacturer's datasheet and published literature.

How should mGluR5 antibodies be validated before experimental use?

Comprehensive validation should include:

• Knockout (KO) validation: Testing in a KO cell line or tissue that does not express mGluR5. A specific antibody produces no signal in KO samples but shows specific signal in wild-type samples . This serves as a true negative control.

• Application-specific validation: Ensure the antibody is validated for your specific application (WB, IHC, ICC, etc.).

• Species validation: Confirm reactivity in your species of interest. For example, Synaptic Systems' mGluR5 antibody (191 508) reacts with mouse and rat and is predicted to cross-react with human due to sequence homology .

• Immunogen sequence alignment: For non-model organisms, check alignment between the antibody's immunogen sequence and your protein of interest using tools like CLUSTALW. An alignment score >85% suggests potential binding .

• Pre-adsorption tests: Incubation with the immunizing peptide should abolish specific signals.

What are the optimal storage and handling conditions for mGluR5 antibodies?

For maximum stability and performance:

• Store lyophilized antibodies at +4°C

• After reconstitution, aliquot and store at -20°C to -80°C

• Avoid freeze-thaw cycles by creating appropriate single-use aliquots

• Do not freeze when still lyophilized

For reconstitution example: Add 50 μl H₂O to get a 1mg/ml solution in PBS, then aliquot and store at -20°C to -80°C until use .

What types of mGluR5 antibodies are available for research?

The following antibody formats are available for mGluR5 research:

• Polyclonal antibodies: Multiple epitope recognition (e.g., GeneTex GTX133288, Abcam ab53090)

• Monoclonal antibodies: Single epitope specificity (e.g., R&D Systems MAB45141)

• Recombinant antibodies: Engineered for consistency (e.g., Synaptic Systems 191 508, a chimeric antibody based on human antibody with rabbit-specific constant regions)

• Patient-derived autoantibodies: Used in mechanistic studies of autoimmune encephalitis

Each type offers distinct advantages depending on the experimental requirements.

How are mGluR5 antibodies used to study neurological disorders?

mGluR5 antibodies have proven valuable in studying several neurological conditions:

Autoimmune encephalitis:
Research has characterized mGluR5 antibody-associated encephalitis using multiple techniques:

• Immunohistochemistry of brain tissue

• Cell-based assays with HEK293 cells expressing mGluR5

• Cultures of hippocampal neurons to study antibody effects on receptor clusters

Clinical features include psychiatric symptoms (10/11 patients), cognitive dysfunction (10/11), movement disorders (7/11), sleep dysfunction (7/11), and seizures (6/11) . The antibodies are predominantly IgG1 subclass and cause a decrease in cell-surface mGluR5.

Ophelia syndrome:
This rare condition involves Hodgkin lymphoma with limbic encephalopathy. Researchers identified mGluR5 as the autoantigen using:

• Immunoprecipitation from cultured neurons

• Mass spectrometry

• Confirmation with mGluR5-null mice

• HEK293 cells transfected with mGluR5 or mGluR1 to test specificity

Prion diseases:
In prion infection models, mGluR5 antibodies reveal increased receptor expression in infected cells:

• Western blot showed higher mGluR5 levels in prion-infected SMB-S15 cells compared to uninfected SMB-PS cells

• Immunofluorescence assays demonstrated more brilliant signals in infected cells

• Real-time PCR confirmed increased mGluR5 mRNA levels (approximately 2.5-fold higher)

What mechanisms underlie the pathogenic effects of anti-mGluR5 autoantibodies?

Patient-derived anti-mGluR5 antibodies affect receptor function through several mechanisms:

• Selective receptor internalization: Patient antibodies cause a significant decrease in mGluR5 cluster density at both synaptic and extrasynaptic locations without affecting other synaptic proteins like PSD95 .

• Receptor cross-linking: The predominant IgG1 subclass likely cross-links and internalizes the receptors, similar to effects reported for antibodies against ionotropic NMDAR or AMPAR .

• Reversible effects: The receptor internalization is reversible when antibodies are removed, with complete recovery of receptor density over 7 days, suggesting functional disruption rather than permanent damage .

• Specificity of effect: Patient IgG specifically decreases cell-surface mGluR5 but not other synaptic proteins such as PSD95 or AMPAR, demonstrated through immunoblot analysis of cell-surface biotinylated proteins .

• Non-cytotoxic mechanism: The effects are likely unrelated to complement- or cell-mediated cytotoxicity, which would cause less reversible deficits. This explains the good clinical response to immunotherapy observed in most patients .

How do antibodies against mGluR5 differ from those against mGluR1 despite their structural homology?

Despite high sequence homology between mGluR5 and mGluR1, antibodies against these receptors show remarkable specificity:

• Distinct epitope recognition: Patient sera containing anti-mGluR5 antibodies do not cross-react with mGluR1, and vice versa. This was demonstrated using HEK293 cells transfected with either receptor .

• Different clinical syndromes: mGluR5 antibodies associate with limbic encephalopathy (Ophelia syndrome), while mGluR1 antibodies are linked to cerebellar ataxia, indicating distinct pathophysiological mechanisms .

• Knockout validation: The specificity of mGluR5 antibodies was definitively demonstrated by the abrogation of patient sera reactivity with brain tissue from mGluR5-null mice .

• Functional effects: Each antibody type likely targets unique functional domains on their respective receptors, leading to distinct patterns of receptor dysfunction.

This specificity is crucial for researchers developing or selecting antibodies for studies involving metabotropic glutamate receptors.

What are the optimal experimental conditions for detecting mGluR5 in different tissue and cell preparations?

Based on published protocols, the following conditions are recommended:

For Immunohistochemistry (IHC):

• Paraffin-embedded human brain sections: Use 25 μg/mL antibody with overnight incubation at 4°C

• Antigen retrieval is typically required for formalin-fixed paraffin-embedded tissues

• Use HRP-DAB detection systems for chromogenic visualization

For Immunocytochemistry/Immunofluorescence (ICC/IF):

• Primary neuronal cultures: Fix in 4% paraformaldehyde (15 minutes at room temperature), use antibody dilution of 1:500

• Co-staining with neuronal markers (e.g., beta-Tubulin 3/Tuj1) helps identify mGluR5-expressing structures

For Western Blotting (WB):

• Dilutions typically range from 1:200 to 1:500 (optimization required)

• Expected molecular weight of ~132 kDa for full-length mGluR5

• Include appropriate positive control (e.g., brain tissue) and negative control (e.g., non-expressing tissue)

Buffer considerations:

• Test both PBS and TBS-based buffers to determine optimal conditions

• pH optimization may be necessary (typically pH 7.2-7.6)

• Incubation times may vary from 1 hour to overnight at 4°C

How can knockout validation be performed to confirm mGluR5 antibody specificity?

Knockout validation provides the most convincing evidence of antibody specificity. Implementation strategies include:

• CRISPR-modified cell lines: Generate cell lines with CRISPR-mediated deletion of mGluR5 gene as negative controls.

• Knockout animal tissues: Use brain or other relevant tissues from mGluR5 knockout mice. Patient sera reactivity was completely abrogated in brain samples from mGluR5-null mice, confirming antibody specificity .

• Commercial knockout resources: Several companies now offer validated knockout cell lines or lysates, saving time compared to generating custom models.

• Validation across multiple applications: Test the antibody in different applications (WB, IF, IHC) using the same knockout samples to ensure consistent specificity.

• Quantitative assessment: Perform quantitative analysis comparing signal intensity between wild-type and knockout samples to demonstrate complete signal abolishment.

Example experimental design:

• Test antibody on wild-type and knockout samples in parallel

• Include positive controls (tissues/cells known to express mGluR5)

• Use identical processing, antibody concentration, and detection methods

• Document complete absence of signal in knockout samples

What are the implications of IgG subclass distribution in anti-mGluR5 autoantibodies?

Analysis of IgG subclasses in patients with anti-mGluR5 encephalitis revealed:

• Predominance of IgG1: The main IgG subclass was IgG1, found in all 9 patients tested, either alone (4/9) or associated with IgG2 (1/9), IgG3 (3/9), or both IgG2 and IgG3 (1/9) .

• Absence of IgG4: None of the patients harbored IgG4 antibodies .

These findings have important mechanistic and clinical implications:

• Internalization mechanism: IgG1 antibodies efficiently cross-link and internalize cell-surface receptors, leading to decreased receptor density rather than direct cytotoxicity.

• Complement activation: IgG1 and IgG3 can activate complement, although the clinical data suggest complement-mediated cytotoxicity is not the primary pathogenic mechanism.

• Treatment implications: The predominance of IgG1 with its reversible effects explains the good response to immunotherapy observed in most patients.

• Disease mechanisms: This profile distinguishes anti-mGluR5 encephalitis from other autoimmune disorders where other IgG subclasses predominate.

The IgG subclass distribution provides insights into pathophysiology and may guide development of targeted therapeutic approaches.

How can researchers determine the epitope specificity of anti-mGluR5 antibodies?

Multiple complementary approaches can determine epitope specificity:

• Domain-specific constructs: Express different domains of mGluR5 (extracellular, transmembrane, intracellular) separately and test antibody binding.

• Peptide scanning: Use overlapping peptide arrays covering the mGluR5 sequence to identify binding regions.

• Competitive binding assays: Test whether known ligands or other antibodies with defined epitopes compete with the antibody of interest.

• Structural analysis: X-ray crystallography or cryo-EM of antibody-antigen complexes provides detailed epitope mapping.

• Mutagenesis studies: Systematic mutation of potential epitope residues to identify critical binding sites.

• Immunoabsorption studies: As used in published research, these can confirm antibody specificity for mGluR5 and help characterize binding regions .

• Anti-idiotypic approaches: Generate anti-idiotypic antibodies that bind to the antigen-binding site of the original antibody to characterize the binding interface .

Understanding epitope specificity is crucial for interpreting experimental results and developing antibodies for specific applications.

What advances in recombinant antibody technology are applicable to mGluR5 research?

Recent developments in recombinant antibody technology offer new possibilities for mGluR5 research:

• Chimeric antibodies: Synaptic Systems' mGluR5 antibody (191 508) exemplifies this approach, with human-derived variable regions combined with rabbit constant regions, allowing use with standard anti-rabbit secondary reagents .

• Intrabody development: Recombinant antibodies expressed intracellularly (intrabodies) can be used as genetically encoded tools to modulate mGluR5 function in living cells .

• Format versatility: Recombinant technology enables generation of various antibody formats:

  • Full IgG molecules

  • Fab fragments

  • Single-chain variable fragments (scFv)

  • Nanobodies (single-domain antibodies)

• Improved consistency: Unlike traditional antibodies, recombinant antibodies have defined sequences ensuring batch-to-batch consistency.

• Affinity maturation: Directed evolution techniques can enhance binding affinity and specificity.

• Novel binding modes: Specialized selection strategies can generate antibodies with distinct binding properties, such as:

  • Type 1: Inhibitory antibodies that block ligand binding

  • Type 2: Non-inhibitory antibodies that detect both free and bound receptor

  • Type 3: Complex-binding antibodies that recognize receptor-ligand complexes

These advances expand the researcher's toolkit for studying mGluR5 function and regulation.

What parameters should be optimized when using mGluR5 antibodies for immunofluorescence studies?

For optimal immunofluorescence results with mGluR5 antibodies, consider these key parameters:

• Fixation protocol optimization:

  • Method: 4% paraformaldehyde for 15 minutes at room temperature works well for neuronal cultures

  • Alternative fixatives (methanol, acetone) may expose different epitopes

  • Overfixation can mask epitopes, while underfixation may compromise morphology

• Antibody dilution and incubation:

  • Start with manufacturer's recommended dilution (typically 1:200-1:500)

  • Perform systematic titration experiment with serial dilutions

  • Test both short (1-2 hours) room temperature and overnight 4°C incubations

• Permeabilization optimization:

  • For intracellular epitopes: 0.1-0.3% Triton X-100 or 0.1% saponin

  • For surface epitopes: omit detergent for live-cell staining

• Blocking conditions:

  • Test different blocking agents (BSA, normal serum from secondary antibody species)

  • Block for sufficient time (minimum 30-60 minutes)

  • Include blocking agent in antibody diluent

• Buffer selection:

  • Compare PBS vs. TBS-based buffers

  • Optimize pH if necessary (typically 7.2-7.6)

• Controls:

  • Positive control: Tissue known to express mGluR5 (e.g., hippocampus)

  • Negative control: Primary antibody omission or knockout tissue

  • Absorption control: Pre-incubation with immunizing peptide

• Signal amplification:

  • Consider tyramide signal amplification for low-expression targets

  • Carefully balance signal strength against background

How can researchers distinguish between cell-surface and intracellular mGluR5 expression?

Differentiating surface from intracellular mGluR5 is crucial for understanding receptor trafficking and function. Effective methods include:

• Non-permeabilized vs. permeabilized staining:

  • Surface detection: Stain live, non-permeabilized cells to detect only cell-surface receptors

  • Total detection: Fix, permeabilize, and stain to detect both surface and intracellular pools

• Surface biotinylation:

  • Selectively label surface proteins with cell-impermeable biotin reagents

  • Isolate biotinylated proteins with streptavidin pulldown

  • Analyze by Western blot to quantify surface mGluR5

• Dual-labeling protocol:

  • Label surface receptors with one fluorophore on live cells

  • Fix, permeabilize, and label total receptor pool with different fluorophore

  • Calculate intracellular fraction by subtraction

• Fluorescence microscopy techniques:

  • Confocal microscopy: Optical sections can distinguish membrane from intracellular staining

  • TIRF microscopy: Selectively visualizes proteins near the plasma membrane

  • Super-resolution microscopy: Provides nanoscale resolution of receptor localization

• Flow cytometry:

  • Compare staining intensity of permeabilized versus non-permeabilized cells

  • Quantify the relative proportions of surface versus total receptor populations

These techniques have been successfully applied in studies of mGluR5 internalization induced by autoantibodies from patients with encephalitis .

How should researchers titrate mGluR5 antibodies for optimal results?

Proper antibody titration is essential for balancing specific signal with minimal background:

• Systematic dilution series:

  • If datasheet suggests 1:200 dilution, test 1:50, 1:100, 1:200, 1:400, and 1:500

  • Use identical samples and experimental conditions for all dilutions

  • Maintain consistent incubation times and temperatures

• Evaluation criteria:

  • Signal intensity at expected localization

  • Signal-to-noise ratio

  • Background levels

  • Specificity (absence of signal in negative controls)

• Application-specific considerations:

  • For WB: Different dilutions may be optimal for different protein amounts

  • For IHC/ICC: Fixation method impacts optimal dilution

  • For flow cytometry: Cell number and fluorophore brightness affect required concentration

• Documentation:

  • Record optimal conditions for each antibody lot

  • When receiving new lot, verify titration results

• Suggested starting dilutions when no recommendation exists:

What controls are essential when working with mGluR5 antibodies?

Implementing comprehensive controls ensures reliable and interpretable results:

• Specificity controls:

  • Knockout tissue/cells (gold standard negative control)

  • Competitive blocking with immunizing peptide

  • siRNA knockdown (partial reduction expected)

  • Secondary antibody only (background assessment)

• Technical controls:

  • Positive control (tissue known to express mGluR5, e.g., hippocampus)

  • Loading controls for WB (housekeeping proteins)

  • Isotype controls for flow cytometry

• Experimental design controls:

  • Concentration matched non-specific IgG

  • Biological replicates (multiple samples)

  • Technical replicates (repeated measurements)

• Application-specific controls:

  • For WB: Molecular weight markers to confirm band size (~132 kDa)

  • For IHC/ICC: Autofluorescence/endogenous peroxidase controls

  • For IP: Pre-immune serum control

• Validation across methods:

  • Confirm findings using multiple detection techniques

  • Use orthogonal methods (e.g., mRNA expression, reporter assays)

How do sample preparation methods affect mGluR5 antibody binding?

Sample preparation significantly impacts epitope accessibility and antibody binding:

• Protein denaturation effects:

  • Some antibodies recognize only denatured epitopes (effective in WB but not IHC)

  • Others recognize only native conformations (effective in flow cytometry or IP)

  • Reducing conditions may expose epitopes normally hidden in folded proteins

• Fixation considerations:

  • Formaldehyde creates methylene bridges between proteins, potentially masking epitopes

  • Alcohol fixatives preserve protein structure differently from aldehyde fixatives

  • Fixation time and temperature affect epitope preservation

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) breaks protein cross-links

  • Proteolytic-induced epitope retrieval uses enzymes to expose epitopes

  • pH of retrieval buffer affects efficiency (citrate pH 6.0 vs. EDTA pH 9.0)

• Frozen vs. paraffin sections:

  • Some antibodies work only on frozen sections

  • Others require paraffin embedding and antigen retrieval

• Cell membrane permeabilization:

  • Required for accessing intracellular epitopes

  • Different detergents (Triton X-100, saponin) affect membrane proteins differently

  • Over-permeabilization can extract membrane proteins

Always check antibody datasheets for recommended sample preparation protocols and be prepared to optimize for your specific experimental system.

What strategies can address non-specific binding of mGluR5 antibodies?

Non-specific binding can complicate interpretation of results. Effective remediation strategies include:

• Optimization of blocking conditions:

  • Increase blocking time (1-2 hours or overnight)

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Add 0.1-0.3% Triton X-100 to blocking buffer to reduce hydrophobic interactions

• Antibody dilution adjustment:

  • Increase dilution (use higher dilution factor)

  • Pre-absorb antibody with non-specific proteins

  • Use purified antibody fractions when available

• Buffer optimization:

  • Add 0.1-0.5M NaCl to reduce ionic interactions

  • Test different pH conditions

  • Add 0.05% Tween-20 to reduce non-specific binding

• Cross-reactivity reduction:

  • When using secondary antibodies, select those pre-adsorbed against potentially cross-reactive species

  • For mouse tissue, use mouse-on-mouse blocking kits to reduce endogenous Ig detection

  • Consider monoclonal or recombinant antibodies with higher specificity

• Technical adjustments:

  • Reduce primary and secondary antibody incubation times

  • Increase wash duration and frequency

  • Filter antibody solutions before use to remove aggregates

• Sample-specific considerations:

  • For fixed tissues, quench autofluorescence with Sudan Black or commercial reagents

  • For peroxidase detection, block endogenous peroxidase activity

  • For biotinylated reagents, block endogenous biotin

How can researchers evaluate mGluR5 antibody quality across different batches?

Maintaining experimental consistency across antibody batches requires systematic validation:

• Initial characterization:

  • Document optimal conditions (dilution, incubation time, buffer)

  • Generate reference images/blots with standardized samples

  • Quantify signal intensity and background levels

• Lot-to-lot testing:

  • Test new antibody lots alongside previous lot

  • Use identical experimental conditions

  • Compare signal intensity, specificity patterns, and background

• Quality metrics:

  • Signal-to-noise ratio

  • Recognition of expected band/pattern

  • Consistent staining intensity at established dilution

  • Reproducible results in knockout validation tests

• Documentation requirements:

  • Record lot numbers

  • Note any adjustment in protocol needed for new lots

  • Maintain reference samples for future comparisons

• Alternative strategies for consistency:

  • Consider recombinant antibodies for improved batch consistency

  • Purchase larger quantities of a single lot for long-term projects

  • Validate multiple antibodies targeting different epitopes

This systematic approach minimizes experimental variability resulting from antibody batch changes.

What approaches can optimize mGluR5 detection in different neuronal populations?

Neuronal subtypes vary in mGluR5 expression levels and subcellular distribution, requiring tailored detection strategies:

• Co-localization with cell-type markers:

  • Neuronal markers: NeuN, MAP2, beta-III tubulin

  • Glial markers: GFAP (astrocytes), Iba1 (microglia)

  • Interneuron markers: Parvalbumin, Somatostatin, Calretinin

• Subcellular localization optimization:

  • Dendritic detection: Co-stain with MAP2

  • Synaptic localization: Co-stain with PSD95 (postsynaptic) or synaptophysin (presynaptic)

  • Membrane vs. intracellular pools: Surface biotinylation or non-permeabilized staining

• Signal amplification strategies:

  • Tyramide signal amplification for low expression levels

  • Super-resolution microscopy for precise localization

  • Proximity ligation assay for protein-protein interactions

• Brain region considerations:

  • Hippocampus: Strong mGluR5 expression in CA1, CA3, and dentate gyrus

  • Cortex: Layer-specific expression patterns

  • Cerebellum: Different expression in Purkinje cells vs. granule cells

• Developmental timepoint awareness:

  • Expression patterns change during development

  • Adjust protocols for embryonic, postnatal, and adult tissues

• Pathological condition adjustments:

  • Expression may be altered in disease states

  • Receptor internalization may occur in autoimmune conditions

  • Upregulation reported in prion-infected cells

These optimizations allow precise characterization of mGluR5 across diverse neuronal populations and experimental conditions.

How might advances in antibody engineering enhance mGluR5 research?

Emerging antibody technologies offer promising opportunities for mGluR5 research:

• Domain-specific functional antibodies:

  • Antibodies targeting specific functional domains (ligand binding, G-protein coupling)

  • Conformation-specific antibodies that recognize active vs. inactive receptor states

  • Phosphorylation state-specific antibodies for signaling studies

• Intrabody applications:

  • Genetically encoded antibody fragments expressed intracellularly

  • Target-specific modulation of receptor trafficking or signaling

  • Fusion with fluorescent proteins for real-time visualization

• Bispecific antibodies:

  • Simultaneous targeting of mGluR5 and interacting proteins

  • Bridge receptor to signaling components

  • Link receptors to visualization or purification tags

• Machine learning optimization:

  • AI-guided antibody design to enhance specificity and affinity

  • Predictive models for antibody-antigen binding

  • Optimized epitope selection for improved performance

• Site-specific conjugation:

  • Precisely positioned fluorophores or functional groups

  • Oriented immobilization for biosensor applications

  • Controlled antibody-drug conjugates for targeted delivery

• Nanobody advantages:

  • Smaller size for improved tissue penetration

  • Access to sterically restricted epitopes

  • Simplified genetic manipulation and expression

These innovations will expand the toolkit for studying mGluR5 localization, function, and dynamics in health and disease.

What role might mGluR5 antibodies play in developing therapeutic approaches?

mGluR5 antibodies have potential applications in diagnostics and therapeutics:

• Diagnostic applications:

  • Biomarkers for autoimmune encephalitis and Ophelia syndrome

  • CSF and serum testing for mGluR5 antibodies in patients with unexplained neuropsychiatric symptoms

  • Monitoring antibody titers to assess treatment response

• Therapeutic antibody development:

  • Function-modulating antibodies (agonists or antagonists)

  • Antibodies that prevent receptor internalization

  • Targeting of specific mGluR5 conformational states

• Treatment monitoring:

  • Tracking autoantibody levels during immunotherapy

  • Correlation between antibody titers and clinical improvement

  • Predicting relapse risk based on persistent antibodies

• Research model applications:

  • Patient-derived antibodies as research tools to understand pathophysiology

  • Development of animal models using passive antibody transfer

  • In vitro models of antibody-mediated receptor internalization

• Combination approaches:

  • Antibodies combined with small molecule modulators

  • Multi-target therapies addressing mGluR5 and related pathways

  • Personalized approaches based on antibody characteristics

The excellent response to immunotherapy observed in patients with anti-mGluR5 encephalitis (complete or partial recovery in all patients) suggests that targeting these antibodies directly could be therapeutically beneficial.